Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer –
NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant.
'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.'
Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine.
About the VERITAC-2 Clinical Trial
The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy.
Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint.
About Vepdegestrant
Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.
The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
15 minutes ago
- New York Post
Nancy Pelosi blows up at Jake Tapper over insider trading allegations
Former House Speaker Nancy Pelosi blew up at CNN's Jake Tapper live on air Wednesday when the broadcaster confronted her about her husband's stock trades and allegations of insider trading. Pelosi, 85, grew testy when presented with a clip of Trump alleging she grew her fortune 'by having inside information' during an interview on 'The Lead with Jake Tapper.' 'Why do you have to read that?' Pelosi (D-Calif.) scoffed as she gesticulated angrily. Advertisement 'We're here to talk about the 60th anniversary of Medicaid. That's what I agreed to come to talk,' she sniped. Tapper noted that he merely 'wanted to give you a chance to respond' to the president's accusations. 'That's ridiculous,' the former House Democratic leader shot back. 'In fact, I very much support the [efforts to] stop the trading of members of Congress.' Advertisement 'Not that I think anybody is doing anything wrong. If they are, they are prosecuted, and they go to jail. But because of the confidence it instills in the American people, don't worry about this.' 4 Nancy Pelosi fumed at questions about her husband's investment activity and accused President Trump of projection. CNN 4 Critics have long raised conflict-of-interest concerns about Nancy Pelosi's family trading. Jack Forbes / NY Post Design Advertisement Concern about congressional stock trading was revived by legislation proposed by Sen. Josh Hawley (R-Mo.) that seeks to ban lawmakers from owning or trading individual stocks. The proposal — dubbed the Preventing Elected Leaders from Owning Securities and Investments (PELOSI) Act — cleared the Senate Homeland Security and Governmental Affairs Committee in an 8–7 vote with support from Democrats and opposition from Republicans on the panel, except Hawley. Initially, Trump expressed interest in the proposal, but later in the day, he publicly lashed out at Hawley, accusing the Missouri senator of helping Democrats 'target' him. Both Trump and Hawley also singled out Pelosi, with Hawley suggesting she might need to be prosecuted over her husband's trades. Advertisement 4 Nancy Pelosi implied that her husband made 'very obvious' trades. REUTERS Paul Pelosi, the California Democrat's venture capitalist husband, has amassed a fortune through investments he's made over the decades. His estimated net worth is $262 million, according to Quiver Quantitative. Numerous reports have highlighted how Paul Pelosi has made several well-timed trades. 'I have no concern about the obvious investments that have been made over time. I'm not into it. My husband is, but it isn't anything to do with anything insider,' Nancy Pelosi told Tapper. 'But the president has his own exposure, so he's always projecting. He's always projecting, and let's not give him any more time on that, please.' Motivating Trump's turn against Hawley over the PELOSI Act appears to be a provision in the bill that applies the ban to presidents and vice presidents. However, that provision would be grandfathered in, meaning it wouldn't apply to Trump or Vice President JD Vance during the president's second term. 4 President Trump has raised questions about how Nancy Pelosi's husband built his fortune. AP Advertisement Pelosi stressed that she is 'very proud' of her family and ripped into Trump for taking swipes at her husband, who was viciously bludgeoned by a sicko in 2022. 'I'd rather not go into some of my other complaints about him right now, rather talk about the 60th anniversary of Medicaid and Medicare,' she said.
UPI
17 minutes ago
- UPI
What is personalized pricing, and how do you avoid it?
Delta Air Lines recently announced it would expand its use of artificial intelligence to provide individualized prices to customers. But personalized pricing can be found ion many industries. Photo by OrnaW/ Pixabay Delta Air Lines recently announced it would expand its use of artificial intelligence to provide individualized prices to customers. This move sparked concern among flyers and politicians. But Delta isn't the only business interested in using AI this way. Personalized pricing has already spread across a range of industries, from finance to online gaming. Customized pricing -- where each customer receives a different price for the same product -- is a holy grail for businesses because it boosts profits. With customized pricing, free-spending people pay more, while the price-sensitive pay less. Just as clothes can be tailored to each person, custom pricing fits each person's ability and desire to pay. I am a professor who teaches business school students how to set prices. My latest book, The Power of Cash: Why Using Paper Money is Good for You and Society, highlights problems with custom pricing. Specifically, I'm worried that AI pricing models lack transparency and could unfairly take advantage of financially unsophisticated people. The history of custom pricing For much of history, customized pricing was the normal way things happened. In the past, business owners sized up each customer and then bargained face-to-face. The price paid depended on the buyer's and seller's bargaining skills -- and desperation. An old joke illustrates this process. Once, a very rich man was riding in his carriage at breakfast time. Hungry, he told his driver to stop at the next restaurant. He went inside, ordered some eggs and asked for the bill. When the owner handed him the check, the rich man was shocked at the price. "Are eggs rare in this neighborhood?" he asked. "No," the owner said. "Eggs are plentiful, but very rich men are quite rare." Custom pricing through bargaining still exists in some industries. For example, car dealerships often negotiate a different price for each vehicle they sell. Economists refer to this as "first-degree" or "perfect" price discrimination, which is "perfect" from the seller's perspective because it allows them to charge each customer the maximum amount they're willing to pay. Currently, most American shoppers don't bargain, but instead see set prices. Many scholars trace the rise of set prices to John Wanamaker's Philadelphia department store, which opened in 1876. In his store, each item had a nonnegotiable price tag. These set prices made it simpler for customers to shop and became very popular. Why uniform pricing caught on Set prices have several advantages for businesses. For one thing, they allow stores to hire low-paid retail workers instead of employees who are experts in negotiation. Historically, they also made it easier for stores to decide how much to charge. Before the advent of AI pricing, many companies determined prices using a "cost-plus" rule. Cost-plus means a business adds a fixed percentage or markup to an item's cost. The markup is the percentage added to a product's cost that covers a company's profits and overhead. The big-box retailer Costco still uses this rule. It determines prices by adding a roughly 15% maximum markup to each item on the warehouse floor. If something costs Costco $100, they sell it for about $115. The problem with cost-plus is that it treats all items the same. For example, Costco sells wine in many stores. People buying expensive champagne typically are willing to pay a much higher markup than customers purchasing inexpensive boxed wine. Using AI gets around this problem by letting a computer determine the optimal markup item by item. What personalized pricing means for shoppers AI needs a lot of data to operate effectively. The shift from cash to electronic payments has enabled businesses to collect what's been called a "gold mine" of information. For example, Mastercard says its data lets companies "determine optimal pricing strategies." So much information is collected when you pay electronically that in 2024, the Federal Trade Commission issued civil subpoenas to Mastercard, JPMorgan Chase and other financial companies demanding to know "how artificial intelligence and other technological tools may allow companies to vary prices using data they collect about individual consumers' finances and shopping habits." Experiments at the FTC show that AI programs can even collude among themselves to raise prices without human intervention. To prevent customized pricing, some states have laws requiring retailers to display a single price for each product for sale. Even with these laws, it's simple to do custom pricing by using targeted digital coupons, which vary each shopper's discount. How you can outsmart AI pricing There are ways to get around customized pricing. All depend on denying AI programs data on past purchases and knowledge of who you are. First, when shopping in brick-and-mortar stores, use paper money. Yes, good old-fashioned cash is private and leaves no data trail that follows you online. Second, once online, clear your cache. Your search history and cookies provide algorithms with extensive amounts of information. Many articles say the protective power of clearing your cache is an urban myth. However, this information was based on how airlines used to price tickets. Recent analysis by the FTC shows the newest AI algorithms are changing prices based on this cached information. Third, many computer pricing algorithms look at your location, since location is a good proxy for income. I was once in Botswana and needed to buy a plane ticket. The price on my computer was about $200. Unfortunately, before booking I was called away to dinner. After dinner my computer showed the cost was $1,000 −- five times higher. It turned out after dinner I used my university's VPN, which told the airline I was located in a rich American neighborhood. Before dinner I was located in a poor African town. Shutting off the VPN reduced the price. Last, often to get a better price in face-to-face negotiations, you need to walk away. To do this online, put something in your basket and then wait before hitting purchase. I recently bought eyeglasses online. As a cash payer, I didn't have my credit card handy. It took five minutes to find it, and the delay caused the site to offer a large discount to complete the purchase. The computer revolution has created the ability to create custom products cheaply. The cashless society combined with AI is setting us up for customized prices. In a custom-pricing situation, seeing a high price doesn't mean something is higher quality. Instead, a high price simply means a business views the customer as willing to part with more money. Using cash more often can help defeat custom pricing. In my view, however, rapid advances in AI mean we need to start talking now about how prices are determined, before customized pricing takes over completely. Jay L. Zagorsky is an associate professor at the Questrom School of Business of Boston University. This article is republished from The Conversation under a Creative Commons license. Read the original article. the views and opinions in this commentary are solely those of the author.
Axios
an hour ago
- Axios
Trump brings back the Presidential Fitness Test in public schools
President Trump will revive the Presidential Fitness Test in public schools, which was phased out more than a decade ago, a White House official confirmed to Axios on Thursday. The big picture: The test — featuring challenges like a one-mile run, pull-ups and the sit-and-reach — was once a rite of passage for America's youth. It was also a source of anxiety and shame for more than a few kids, who ended up feeling like they weren't strong enough for the president's (or Arnold Schwarzenegger ' s) purposes. Trump on Thursday will sign an executive order to reestablish the President's Council on Sports, Fitness and Nutrition, which includes re-establishing the test, as first reported by CNN. Why it matters: The Trump administration has focused on sports and athletics, including banning transgender athletes and hosting major national and international sporting events. State of play: Then-President Dwight D. Eisenhower established the test in 1956 to assess cardiovascular fitness, upper body and core strength, endurance, flexibility and agility, according to Harvard Health. The test included a one-mile run, pull-ups or push-ups, sit-ups, shuttle run, and sit-and-reach. Children in the top 15% received the Presidential Physical Fitness Award, established by former President Lyndon B. Johnson. President Obama replaced the test after the 2012-13 school year and instituted the Presidential Youth Fitness Program, putting more emphasis on students' health rather than performance, per Education Week. Flashback: Eisenhower originally established the test out of panic over American children being less fit than European children, Vox reported. One of its early iterations was akin to a military training exercise. What's next: The Presidential Fitness test will be administered by Health and Human Services Secretary Robert F. Kennedy Jr. The executive order directs the council to create school programs rewarding excellence in physical education and develop criteria for a fitness award. What they're saying: "President Trump wants to ensure America's future generations are strong, healthy, and successful," White House press secretary Karoline Leavitt said in a statement.
